Table 2.
Secondary End Points
| Secondary End Points | Placebo Group | BCG Vaccine Group | SHR (95% CI)a | ||
|---|---|---|---|---|---|
| Events, No. | Cumulative Incidence (95% CI) | Events, No. | Cumulative Incidence (95% CI) | ||
| Documented SARS-CoV-2 infection | 48 | 0.049 (.037–.064) | 51 | 0.051 (.039–.066) | 1.053 (.710–1.562) |
| Resulting in death | 0 | 0.000 | 1 | 0.001 (.000–.006) | NA |
| Resulting in ICU admission | 1 | 0.001 (.000–.006) | 0 | 0.000 | NA |
| Resulting in hospital stay | 1 | 0.001 (.000–.006) | 2 | 0.002 (.000–.007) | 1.978 (.165–23.773) |
| Self-reported RTI irrespective of medical intervention | 338 | 0.345 (.315–.376) | 351 | 0.355 (.325–.386) | 1.055 (.909–1.225) |
Abbreviations: CI, confidence interval; ICU, intensive care unit; NA, not applicable; RTI, respiratory tract infection; SARS, severe acute respiratory syndrome coronavirus 2; SHR, subdistribution hazard ratio.
SHRs are adjusted for stratification variables (site and age category) and for cardiovascular disease (including hypertension), diabetes, and chronic pulmonary disease.